Citations

Mayo Clinic

Showing 10 of 108523 citations.

Safety and efficacy profile of belzutifan, a hypoxia-inducible factor-2α inhibitor, in patients with renal cell carcinoma: Meta-analysis and systematic review.
Shafique, Nouman, Javeed, Zainab, Bajwa, Shammas, Ghaffar, Umar , Muhibullah, Zain, Sarmad, Kaur, Navneet, Ghaffar, Ali , Kunwar, Digbijay , Farooqui, Sabeeh Khawar, Iqbal, Abdul Ghani, Naqvi, Syed Mujtaba Ali, Qadeer, Abdul , Ehsan, Amna, Shafique, Adeena , Rizwan, Umer, Hussain, Rida, LOHANA, ABHI , Ahmed, Jawad , Naqvi, Syed , Shafiq, Iqra

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e16531-e16531

10.1200/jco.2024.42.16_suppl.e16531 Get It

e16531 Background: Hypoxia-inducible Factor-2α (HIF-2α) is a transcription factor that accumulates in clear cell renal cell carcinoma (ccRCC) and is responsible for genes involved in oncogenesis. Belzutifan is a HIF-2α inhibitor that has shown promising anti-tumor effects in patients with ccRCC. Our objective is to summarize the available literature on the safety and efficacy profile of the drug. Methods: An electronic search was conducted on PubMed, Embase, and Cochrane from inception till January 31st, 2024. We identified patients aged ≥ 18 years with ccRCC who received Belzutifan. We extracted data on objective response rate, complete response rate, any grade adverse effect (AE) and grade ≥3 AE. Data was analyzed using R (v.4.3) and reported as proportions with respective 95% confidence intervals (CI) on forest plots. Results: Three studies (n=168 patients) were identified that reported the use of Belzutifan in ccRCC. Our analysis showed that pooled proportion of objective response rate and complete response rate was 35% (95% CI: 24% – 47%) and 1% (95% CI: 0% – 5%) respectively. Pooled proportion of patients experiencing any grade AE and grade ≥3 AE was 98% (95% CI: 95% – 99%) and 49% (95% CI: 29% – 69%) respectively. Conclusions: Belzutifan is a novel drug that inhibits HIF-2α which in turn results in anti-tumor effects of the drug against ccRCC. The drug has an acceptable safety and efficacy profile from limited data but more studies are needed to establish a complete picture of drug’s adverse effects and clinical benefits. Pooled proportion of patients developing (A) Objective Response, (B) Complete response (C) Any adverse effect and (D) Grade ≥3 adverse effects. [Table: see text]
Small Bowel Follow-Through in the Age of Cross-sectional Imaging
Moran, Shamus , Abadi, Alireza , DiSantis, David J. , Revels, Jonathan , Rohrmann, Charles A., Bhargava, Puneet , Mansoori, Bahar , DiSantis, David , Rohrmann, Charles, Revels, Jonathan W , Moran, Shamus K

RadioGraphics | June 6, 2024 | Volume: 44 | Issue: 7 | Pages: No page available

10.1148/rg.230135 | PMID 38843095 Get It

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Camidge, D. Ross , Bar, Jair , Goldman, Jonathan W. , Moiseenko, Fedor , Филиппова, Е. А. , Çiçin, İrfan , Daaboul, Nathalie , Liu, Chunling , Bradbury, Penelope A., Moskovitz, Mor, Katgı, Nuran , Cuppens, Kristof , Wu, Shang‐Yin , Baijal, Shobhit , Kuo, Chih‐Hsi S. , Planchard, David , Baik, Christina S. , Li, Martha, Ansell, Peter , Xia, Summer, Bolotin, Ellen, Looman, Jim, Ratajczak, Christine K. , Horinouchi, Hidehito , Goldman, Jonathan W , Moiseenko, Fedor , Cicin, Irfan , Zer Kuch, Alona , Girard, Nicolas , Cuppens, Kristof , Han, Ji-Youn , Wu, Shang-Yin , Mansfield, Aaron S , Kuo, Chih-Hsi , Nishino, Kazumi , Lee, Se-Hoon , Planchard, David , Lu, Shun , Filippova, Elena, Ciuleanu, Tudor–Eliade , Tomasini, Pascale , Girard, Nicolas , Mansfield, Aaron S.

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 25 | Pages: 3000-3011

10.1200/jco.24.00720 | PMID 38843488 Get It

PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optimal c-Met protein–overexpressing non–small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage I) and expand the selected group for efficacy evaluation (stage II). Stage II enrolled patients with nonsquamous epidermal growth factor receptor ( EGFR )-wildtype NSCLC. METHODS Eligible patients had locally advanced/metastatic c-Met protein–overexpressing NSCLC and ≤2 previous lines of therapy (including ≤1 line of systemic chemotherapy). c-Met protein overexpression in nonsquamous EGFR -wildtype NSCLC was defined as ≥25% tumor cells with 3+ staining (high [≥50% 3+]; intermediate [≥25%–<50%]). Teliso-V was administered at 1.9 mg/kg once every 2 weeks. The primary end point was overall response rate (ORR) by independent central review. RESULTS In total, 172 patients with nonsquamous EGFR -wildtype NSCLC received Teliso-V in stages I and II. ORR was 28.6% (95% CI, 21.7 to 36.2; c-Met high, 34.6% [95% CI, 24.2 to 46.2]; c-Met intermediate, 22.9% [95% CI, 14.4 to 33.4]). The median duration of response was 8.3 months (95% CI, 5.6 to 11.3; c-Met high, 9.0 [95% CI, 4.2 to 13.0]; c-Met intermediate: 7.2 [95% CI, 5.3 to 11.5]). The median overall survival was 14.5 months (95% CI, 9.9 to 16.6; c-Met high, 14.6 [95% CI, 9.2 to 25.6]; c-Met intermediate, 14.2 [95% CI, 9.6 to 16.6]). The median progression-free survival was 5.7 months (95% CI, 4.6 to 6.9; c-Met high, 5.5 [95% CI, 4.1 to 8.3]; c-Met intermediate: 6.0 [95% CI, 4.5 to 8.1]). Most common any-grade treatment-related adverse events (AEs) were peripheral sensory neuropathy (30%), peripheral edema (16%), and fatigue (14%); the most common grade ≥3 AE was peripheral sensory neuropathy (7%). CONCLUSION Teliso-V was associated with durable responses in c-Met protein–overexpressing nonsquamous EGFR -wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.
Nocturnal Hypoxemia is Associated with Sarcopenia in Patients with Chronic Obstructive Pulmonary Disease
Attaway, Amy , Zein, Joe , Hatipoğlu, Umur , Grund, Megan E. , Orsini, E.M. , Olman, Mitchell A. , Attaway, Amy H , Zein, Joe G, Mehra, Reena , Scheraga, Rachel Greenberg , Dasarathy, Srinivasan

Annals of the American Thoracic Society | June 6, 2024 | Volume: 21 | Issue: 9 | Pages: 1316-1325

10.1513/annalsats.202312-1062oc | PMID 38843487 Get It

Abstract Rationale Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Our previous studies have identified that nocturnal hypoxemia causes skeletal muscle loss (i.e., sarcopenia) in in vitro models of COPD. Objectives We aimed to extend our preclinical mechanistic findings by analyzing a large sleep registry to determine whether nocturnal hypoxemia is associated with sarcopenia in patients with COPD. Methods Sleep studies from patients with COPD (n = 479) and control subjects without COPD (n = 275) were analyzed. Patients with obstructive sleep apnea, as defined by apnea–hypopnea index ⩾ 5, were excluded. Pectoralis muscle cross-sectional area (PMcsa) was quantified using computed tomography scans performed within 1 year of the sleep study. We defined sarcopenia as less than the lowest 20% residuals for PMcsa of control subjects, which was adjusted for age and body mass index (BMI) and stratified by sex. Youden’s optimal cut-point criteria were used to predict sarcopenia based on mean oxygen saturation during sleep. Additional measures of nocturnal hypoxemia were analyzed. The pectoralis muscle index (PMI) was defined as PMcsa normalized to BMI. Results On average, males with COPD had a 16.6% lower PMI than control males (1.41 ± 0.44 vs. 1.69 ± 0.56 cm2/BMI; P &lt; 0.001), whereas females with COPD had a 9.4% lower PMI than control females (0.96 ± 0.27 vs. 1.06 ± 0.33 cm2/BMI; P &lt; 0.001). Males with COPD with nocturnal hypoxemia had a 9.5% decrease in PMI versus COPD with normal O2 (1.33 ± 0.39 vs. 1.47 ± 0.46 cm2/BMI; P &lt; 0.05) and a 23.6% decrease compared with control subjects (1.33 ± 0.39 vs. 1.74 ± 0.56 cm2/BMI; P &lt; 0.001). Females with COPD with nocturnal hypoxemia had an 11.2% decrease versus COPD with normal O2 (0.87 ± 0.26 vs. 0.98 ± 0.28 cm2/BMI; P &lt; 0.05) and a 17.9% decrease compared with control subjects (0.87 ± 0.26 vs. 1.06 ± 0.33 cm2/BMI; P &lt; 0.001). These findings were largely replicated using multiple measures of nocturnal hypoxemia. Conclusions We defined sarcopenia in the pectoralis muscle using residuals that take into account age, BMI, and sex. We found that patients with COPD have a lower PMI than patients without COPD and that nocturnal hypoxemia was associated with an additional decrease in the PMI of patients with COPD. Additional prospective analyses are needed to determine a protective threshold of oxygen saturation to prevent or reverse sarcopenia due to nocturnal hypoxemia in COPD.
Making Clozapine Therapeutic Drug Monitoring Essential for Optimal Patient Care
Leung, Jonathan G. , Bye, Katie N., Leloux, Megan R. , Markota, Matej , Allen, Nicholas D. , Leung, Jonathan G

Therapeutic Drug Monitoring | June 6, 2024 | Volume: 46 | Issue: 6 | Pages: 837-838

10.1097/ftd.0000000000001233 | PMID 38842546 Get It

Actigraphy-based sleep and muscle sympathetic nerve activity in humans
Bigalke, Jeremy A. , Greenlund, Ian M. , Bigalke, Jennifer R., Carter, Jason R , Bigalke, Jeremy A , Bigalke, Jennifer R., Carter, Jason R.

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | June 6, 2024 | Volume: 327 | Issue: 2 | Pages: R145-R151

10.1152/ajpregu.00113.2024 | PMID 38842513 Get It

The present study investigated the independent association between actigraphy-based sleep duration, efficiency, and measures of blood pressure, heart rate, and muscle sympathetic nerve activity (MSNA) in adult males and females. Contrary to our hypothesis, the findings do not support an independent association between habitual sleep and cardiovascular or sympathetic neural activity. However, these findings do not preclude a potential association between these parameters in populations with sleep disorders and/or cardiovascular disease.
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference
Miller, Wayne L. , Grill, Diane E. , Mullan, Brian P., Miller, Wayne L.

Circulation: Heart Failure | June 6, 2024 | Volume: 17 | Issue: 6 | Pages: No page available

10.1161/circheartfailure.123.010906 | PMID 38842508 Get It

BACKGROUND: Blood volume (BV) profiles vary markedly in patients with heart failure (HF), but how HF phenotypes and patient sex impact volume profiles remain to be explored. The aim of the study was to differentiate BV, plasma volume, and red blood cell mass profiles by phenotypes of preserved and reduced left ventricular ejection fractions and assess the impact of patient sex on profile heterogeneity. METHODS: Retrospective analysis of clinical and BV data was undertaken in patients with chronic New York Heart Association II–III heart failure. BV was quantitated using the nuclear medicine indicator-dilution methodology. RESULTS: A total of 530 BV analyses (360 HF with reduced ejection fraction and 170 HF with preserved ejection fraction) were identified in 395 unique patients. Absolute BV was greater in HF with reduced ejection fraction (6.7±1.8 versus 5.9±1.6 liters: P <0.001); however, large variability in frequency distribution of volume profiles was observed in both phenotypes (−22% deficit to +109% excess relative to normal volumes). HF with reduced ejection fraction was characterized by a higher prevalence of BV expansion ≥+25% of normal (39% versus 26%; P =0.003), and HF with preserved ejection fraction was characterized a by more frequent normal BV (42% versus 24%; P <0.001). Male sex in both phenotypes was associated with a larger absolute BV (7.0±1.6 versus 5.1±1.3 liters; P <0.001) and higher frequency of large BV and plasma volume expansions above normal (both P <0.001), while females in both phenotypes demonstrated a higher prevalence of normal BV and plasma volume (both P <0.001). CONCLUSIONS: Findings support significant differences in BV, plasma volume, and red blood cell mass profile distributions between heart failure phenotypes, driven in large part by sex-specific factors. This underscores the importance of identifying and distinguishing individual patient volume profiles to help guide volume management strategies.
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, Jennifer E. , Stalnecker, Clint A. , Bryant, Kirsten L. , Edwards, A. Cole , Drizyte‐Miller, Kristina , Hibshman, Priya S. , Diehl, J. Nathaniel , Lee, Ye S. , Morales, Alexis Jean , Taylor, Khalilah E. , Peng, Sen, Tran, Nhan L. , Prevatte, Alex W., Hover, Laura D. , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Olson, Peter , Christensen, James G. , Graves, Lee M. , Wennerberg, Krister , Klomp, Jeffrey A , Klomp, Jennifer E , Stalnecker, Clint A , Bryant, Kirsten L , Drizyte-Miller, Kristina , Diehl, J Nathaniel , Lee, Ye S , Morales, Alexis J , Taylor, Khalilah E , Herring, Laura E , Barker, Natalie K , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Lee, Hey Min , Goodwin, Craig M , Gautam, Prson , Olson, Peter , Christensen, James G , Shen, John P , Kopetz, Scott , Graves, Lee M , Lim, Kian-Huat , Wang-Gillam, Andrea , Wennerberg, Krister , Cox, Adrienne D , Der, Channing J , Tran, Nhan L , Herring, Laura E. , Barker, Natalie K. , Gautam, Prson , Kopetz, Scott , Wang‐Gillam, Andrea , Cox, Adrienne D.

Science | June 6, 2024 | Volume: 384 | Issue: 6700 | Pages: No page available

10.1126/science.adk0775 | PMID 38843331 Get It

How the KRAS oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal–regulated kinase (ERK)–dependent gene transcription in KRAS-mutant cancer to delineate the molecular mechanisms of growth and of inhibitor resistance. Unexpectedly, our KRAS-dependent gene signature diverges substantially from the frequently cited Hallmark KRAS signaling gene signature, is driven predominantly through the ERK mitogen-activated protein kinase (MAPK) cascade, and accurately reflects KRAS- and ERK-regulated gene transcription in KRAS-mutant cancer patients. Integration with our ERK-regulated phospho- and total proteome highlights ERK deregulation of the anaphase promoting complex/cyclosome (APC/C) and other components of the cell cycle machinery as key processes that drive pancreatic ductal adenocarcinoma (PDAC) growth. Our findings elucidate mechanistically the critical role of ERK in driving KRAS-mutant tumor growth and in resistance to KRAS-ERK MAPK targeted therapies.
Left Atrial Function and Volume Associations with Hemodynamics in a Representative Aged Cohort: Unlocking New Insights
Collins, Jeremy D. , Collins, Jeremy

Radiology: Cardiothoracic Imaging | June 6, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1148/ryct.240054 | PMID 38842458 Get It

Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema
Fortis, Spyridon , Guo, Junfeng , Chaudhary, Muhammad F. A. , Newell, John D. , Gerard, Sarah E. , Han, MeiLan K., Kazerooni, Ella A. , Bodduluri, Sandeep, Paine, Robert , Awan, Hira A. , Schroeder, Joyce , Gravens‐Mueller, Lisa, Ortega, Victor E. , Anderson, Wayne H. , Cooper, Christopher B. , Woodruff, Prescott G. , Bhatt, Surya P. , Hoffman, Eric A. , Comellas, Alejandro P. , Bowler, Russell P , Hoffman, Eric A , Comellas, Alejandro P , Fortis, Spyridon , Bhatt, Surya P , Nagpal, Prashant , Han, MeiLan King , Martínez, Fernando J. , Barjaktarević, Igor , Barr, R. Graham , Bodduluri, Sandeep , Couper, David , Bowler, Russell P. , Reinhardt, Joseph M.

American Journal of Respiratory and Critical Care Medicine | June 6, 2024 | Volume: 210 | Issue: 12 | Pages: 1432-1440

10.1164/rccm.202310-1825oc | PMID 38843116 Get It

Abstract Rationale Ground-glass opacities (GGOs) in the absence of interstitial lung disease are understudied. Objectives To assess the association of GGOs with white blood cells (WBCs) and progression of quantified chest computed tomography emphysema. Methods We analyzed data of participants in the SPIROMICS study (Subpopulations and Intermediate Outcome Measures in COPD Study). Chest radiologists and pulmonologists labeled regions of the lung as GGOs, and the adaptive multiple feature method (AMFM) trained the computer to assign those labels to image voxels and quantify the volume of the lung with GGOs (%GGOAMFM). We used multivariable linear regression, zero-inflated negative binomial, and proportional hazards regression models to assess the association of %GGOAMFM with WBCs, changes in percentage emphysema, and clinical outcomes. Measurements and Main Results Among 2,714 participants, 1,680 had chronic obstructive pulmonary disease (COPD) and 1,034 had normal spirometry. Among participants with COPD, on the basis of multivariable analysis, current smoking and chronic productive cough were associated with higher %GGOAMFM. Higher %GGOAMFM was cross-sectionally associated with higher WBC and neutrophil concentrations. Higher %GGOAMFM per interquartile range at visit 1 (baseline) was associated with an increase in emphysema at 1-year follow-up visit by 11.7% (relative increase; 95% confidence interval, 7.5–16.1%; P &lt; 0.001). We found no association between %GGOAMFM and 1-year FEV1 decline, but %GGOAMFM was associated with exacerbations and all-cause mortality during a median follow-up of 1,544 days (interquartile interval, 1,118–2,059). Among normal spirometry participants, we found similar results, except that %GGOAMFM was associated with progression to COPD at 1-year follow-up. Conclusions Our findings suggest that GGOAMFM is associated with increased systemic inflammation and emphysema progression.